DBV Technologies Investor Relations Material
Latest events
Q2 2024
DBV Technologies
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from DBV Technologies S.A.
Access all reports
DBV Technologies, S.A. is a clinical-stage biopharmaceutical company engaged in the research and development of epicutaneous immunotherapy (EPI) products to treat cancer and dermatology. The company's EPI technology platform includes monoclonal antibodies, passive transport devices using microelectrode arrays, and a wide variety of fully human anti-cancer antibodies
Latest articles
Qualcomm: Quality Communication and Semiconductor Innovation
Founded in 1985, Qualcomm has transformed the digital communication industry with CDMA technology and its advanced semiconductor business.
13 Sep 2024
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
Ticker symbol
DBV
Country
🇫🇷 France